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Background: The histone deacetylase inhibitor vorinostat is a candidate radiosensitizer in locally advanced rectal
cancer (LARC). Radiosensitivity is critically influenced by hypoxia; hence, it is important to evaluate the efficacy of
potential radiosensitizers under variable tissue oxygenation. Since fluoropyrimidine-based chemoradiotherapy (CRT)
is the only clinically validated regimen in LARC, efficacy in combination with this established regimen should be
assessed in preclinical models before a candidate drug enters clinical trials.
Methods: Radiosensitization by vorinostat under hypoxia was studied in four colorectal carcinoma cell lines and in
one colorectal carcinoma xenograft model by analysis of clonogenic survival and tumor growth delay, respectively.
Radiosensitizing effects of vorinostat in combination with capecitabine were assessed by evaluation of tumor
growth delay in two colorectal carcinoma xenografts models.
Results: Under hypoxia, radiosensitization by vorinostat was demonstrated in vitro in terms of decreased
clonogenicity and in vivo as inhibition of tumor growth. Adding vorinostat to capecitabine-based CRT increased
radiosensitivity of xenografts in terms of inhibited tumor growth.
Conclusions: Vorinostat sensitized colorectal carcinoma cells to radiation under hypoxia in vitro and in vivo and
improved therapeutic efficacy in combination with capecitabine-based CRT in vivo. The results encourage
implementation of vorinostat into CRT in LARC trials.
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In locally advanced rectal cancer (LARC), neoadjuvant
chemoradiotherapy (CRT) is given to obtain tumor down-
staging to allow complete surgical removal, and single-
agent fluoropyrimidine in combination with fractionated
pelvic radiation remains the standard regimen [1]. Treat-
ment responses vary considerably, and this may be par-
ticularly important in large T4 tumors that depend greatly
on the effect of neoadjuvant CRT for preoperative down-* Correspondence: kjersti.flatmark@rr-research.no
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reproduction in any medium, provided the orstaging [2]. Other potential radiosensitizing agents have
been evaluated for their ability to further enhance local
tumor response, but improvement has so far not been
achieved, warranting the continued search for novel radio-
sensitizers [3-6]. Histone deacetylase (HDAC) inhibitors
have emerged as a new class of drugs that has been shown
to sensitize tumors to radiation in experimental models.
We have previously assessed the radiosensitizing ability of
the HDAC inhibitor vorinostat in experimental colorectal
carcinoma models, demonstrating reduced in vitro clono-
genicity upon radiation exposure and delayed tumor
growth of xenografts exposed to fractionated radiation [7].
In a recent clinical phase I study, we reported a favorableLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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palliative radiotherapy [8,9].
As recently highlighted in guidelines from the NCRI
Clinical and Translational Radiotherapy Research Work-
ing Group [10], novel radiosensitizers must be ad-
equately evaluated in relevant preclinical models in
order to justify exposing patients to the risks of adding a
new drug to radiotherapy or CRT. Since human solid
tumors, including rectal carcinomas, often contain a
substantial fraction of hypoxic cells that are intrinsically
more resistant to radiotherapy, a drug’s ability to radio-
sensitize tumor cells under hypoxia should be taken into
account when investigating new CRT candidates [11].
Furthermore, since fluoropyrimidine-based CRT is the
established regimen in LARC, potential interaction be-
tween a new drug and the standard treatment should be
investigated to reveal possible antagonistic or synergistic
effects. In the present work, radiosensitizing effects of
vorinostat were assessed under hypoxic conditions in
four colorectal carcinoma models in vitro and in one
xenograft model. Moreover, radiosensitizing properties
of vorinostat in combination with the fluoropyrimidine
capecitabine were investigated in two colorectal carcin-
oma xenograft models.Methods
Experimental treatments
Ionizing radiation (IR) was delivered to cell lines in cul-
ture at a rate of 1.0 Gy/min by Faxitron Cabinet X-ray
system (model 43855 F with CP 160 Option; Faxitron
Bioptics, Lincolnshire, IL). Control cells were simultan-
eously placed in room temperature. To tumor xenografts,
IR was delivered in daily 2-Gy fractions using a 6-MV
photon beam from a linear accelerator (Varian Clinac
2100 CD; Varian, San Diego, CA), at a dose rate of
2.6 Gy/min. Control mice were anaesthetized and
brought to the radiation room. Vorinostat (Alexis
Biochemicals, Lausen, Switzerland) and capecitabine
(Roche, Basel, Switzerland) were prepared and stored as
previously described [7].
In experiments involving hypoxia, the following
single agent and combination treatments were given:
C (control) =NO (normoxia), HO (hypoxia), IR-NO (IR
under normoxia), IR-HO (IR under hypoxia), VOR-NO
(vorinostat under normoxia), VOR-HO (vorinostat under
hypoxia), VOR-IR-NO (vorinostat and IR under nor-
moxia), and VOR-IR-HO (vorinostat and IR under
hypoxia). For experiments involving combination of vor-
inostat and capecitabine, the following treatments were
given: C (control), VOR (vorinostat), CAP (capecitabine),
IR, VOR-IR (vorinostat and IR), CAP-IR (capecitabine
and IR), and VOR-CAP-IR (vorinostat, capecitabine,
and IR).Cell lines and in vitro experiments
Human colorectal carcinoma cell lines HCT116, HT29,
and SW620 (ATCC, Manassas, VA) and KM20L2 (kindly
provided by Dr. M. R. Boyd, National Cancer Institute,
Frederick, MD) were used. The cell lines were free from
mycoplasma infection and cell line identity was validated
by short tandem repeat analysis. Culturing conditions
were previously described [7]. Vorinostat (1 or 2 μM)
was added to the cell cultures for an incubation period
of 18 h. In vitro hypoxia (1% O2) was generated using an
Invivo2 200 Hypoxic Workstation (Ruskinn, Bridgend,
UK). Cell cultures were incubated under these condi-
tions for 18 h before sealing the flasks using non-filter
caps and transferring them to an x-ray unit. After IR ex-
posure, culture flasks were transferred to normoxic con-
ditions. Control cell cultures were kept under normoxic
conditions at all times. Clonogenicity was performed as
previously described [7] with the main modification
being that cells were grown in T-25 flasks (Nunc, Ros-
kilde, Denmark) to allow generation of hypoxia. Plating
efficiencies determined from control experiments were
0.63 ± 0.07 for HCT116, 0.84 ± 0.19 for HT29, 0.61 ± 0.14
for SW620, and 0.78 ± 0.08 for KM20L2. Surviving frac-
tions (SF) were calculated relative to the relevant
control.
For analysis of HIF-1α induction, HCT116 cells were
seeded in cell culture flasks and exposed to HO or NO
as previously described or treated with 100 μM CoCl2
for 4 h to generate a positive control for HIF-1α expres-
sion (Sigma Aldrich, St Louis, MO). Whole cells lysates
were generated as previously described [12] and stored
at - 80°C until analysis. Separation of 7.5 μg of protein
was performed using 4-12% NuPAGEW Novex Bis-Tris
Gels (Invitrogen, Carlsbad, CA) in MES buffer and
transferred to Immobilon-P membranes (Millipore, Bed-
ford, MA). Membranes were blocked for 1 h at room
temperature in Tris-buffered saline with 0.1% Tween-20
(TBST) and 5% non fat dry milk and incubated over night
at 4°C with mouse anti-HIF-1α antibody (# 610958; BD
Transduction Laboratories, Franklin Lakes, NJ) or goat
anti-actin antibody (sc-1616; Santa Cruz Biotechnology,
Santa Cruz, CA). After washing, the membranes were
incubated for 1 h at room temperature with appropriate
horseradish peroxidase conjugated secondary antibody,
and bands were visualized using Super Signal West
Dura Extended Duration Substrate (Thermo Scientific,
Waltham, MA).
Animal models
Locally bred female and male athymic Balb/c mice 6–
8 weeks old were used. For one experiment (vorinostat,
capecitabine, and IR– in vivo tumor growth, HCT116
xenografts) Balb/c nude (nu/nu) mice from Harlan La-
boratories (Rossdorf, Germany) were purchased, as our
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due to relocation of the department. The mice were
maintained under specific pathogen-free conditions, and
food and water were supplied ad libitum. Housing and
all procedures involving animals were performed according
to protocols approved by the Animal Care and Use Com-
mittee, in compliance with the National Committee for
Animal Experiment’s guidelines on animal welfare. Xeno-
grafts were established as previously described [7] on the
thigh (hypoxia experiments) or on the rear flank (capecita-
bine experiments) and tumor volumes were calculated
using the following formula: volume= (п/6) × a×b2, in
which a and b were the largest and the smallest perpen-
dicular tumor diameters, respectively. The mice were sacri-
ficed when tumors reached a diameter of 15 mm (thigh) or
20 mm (flank), or if the animal failed to thrive.
In vivo experiments
In vivo tumor hypoxia was achieved by placing a heavy
clamp over the proximal thigh of anesthetized mice dur-
ing irradiation [13]. The tumors were clamped for
3.5 min before and during IR exposure (to a total period
of 5.0 min). In experiments involving hypoxia, the mice
were randomized by tumor volume into groups of 5–6
animals and were treated with vorinostat concomitantly
to irradiation for four consecutive days. Vorinostat
(100 mg/kg) or vehicle was given daily by intraperitoneal
(i.p.) injections three hours before radiation. Tumor
blood supply to clamped xenografts was examined by
measuring tumor radioactivity after injection of I125 and
used as a measure of acute hypoxia. I125 (Hartmann
Analytic, Braunschweig, Germany) in the form of an
iodinated antibody and with an activity of 2.85 MBq/ml,
was administered by tail vein injection (100 μL, mean
activity of 10 kBq/g) to four anesthetized mice (tumor
volume 91.3 ± 34.3 mm3; mean ± standard deviation).




Monotherapy (relative to control)
IR 0.029 (0.04) <0.001 0.33 (0.02
HO 0.97 (0.08) 0.7 0.98 (0.03
VOR 0.35 (0.04) <0.001 0.78 (0.07
Combination therapy
IR-HO (relative to HO) 0.13 (0.03) <0.001 0.51 (0.05
VOR-HO (relative to HO) 0.41 (0.05) <0.001 0.88 (0.09
VOR-IR (relative to VOR) 0.011 (0.004) <0.001 0.18 (0.03
VOR-IR-HO (relative to VOR-HO) 0.020 (0.005) <0.001 0.24 (0.02
SF = surviving fractions; HO= hypoxia; VOR = vorinostat; IR-HO= IR under hypoxia;
VOR-HO= vorinostat under hypoxia; VOR-IR = vorinostat and IR; VOR-IR-HO= vorinosdissected and clamped and unclamped tumors were ana-
lyzed by a gamma counter (COBRA II Auto-Gamma;
Packard Canberra, Meriden, CT). The ratio of I125 activ-
ity (i.e., activity in clamped tumor divided by activity in
unclamped tumor on the same mouse) was 0.03 ± 0.01
(mean ± standard deviation), indicating a substantial re-
duction of blood flow to clamped tumors (p < 0.001).
In experiments involving capecitabine, the mice were
randomized by tumor volume into treatment groups of 6–
9 mice and treated with vorinostat concomitantly to irradi-
ation for five consecutive days. Vorinostat (100 mg/kg) or
vehicle was given daily by i.p. injections three hours before
radiation. Capecitabine (359 mg/kg) or vehicle was given
daily by oral gavage immediately after administration of
vorinostat. Relative tumor volumes (RTV) were calculated
relative to the tumor volume on the day of treatment initi-
ation. For each tumor, tumor doubling time (T2x) relative
to the Day 1 tumor volume was determined. Tumor
growth delay (TGD2x) was calculated by subtracting the
mean T2x of the vehicle-treated tumors from the T2x for
each treated xenograft.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (SPSS
Inc., Chicago, IL). Differences between groups were
analyzed using the two-sided Student t test under con-
ditions of normality and a non-parametric test (Mann–
Whitney rank-sum test) under other conditions. p values
less than 0.05 were considered statistically significant.
Results
Vorinostat, hypoxia, and IR – in vitro clonogenicity
In initial experiments on HCT116 cells, clonogenicity
was not influenced by hypoxia (SF for HO cells was
0.97 ± 0.08; mean ± standard error of the mean, com-
pared to C). Likewise, the survival of VOR-NO cells and
VOR-HO cells was similar (SF were 0.35 ± 0.04 and) after treatment with ionizing radiation (IR, 5 Gy),
T29 SW620 KM20L2
p SF p SF p
) <0.001 0.079 (0.02) <0.001 0.11 (0.002) <0.001
) 0.6 0.62 (0.28) 0.3 0.92 (0.01) 0.01
) 0.05 0.84 (0.04) 0.07 0.66 (0.04) 0.04
) 0.002 0.36 (0.10) 0.02 0.20 (0.02) <0.001
) 0.3 0.68 (0.14) 0.1 0.68 (0.03) 0.08
) <0.001 0.026 (0.02) <0.001 0.066 (0.02) <0.001
) <0.001 0.052 (0.03) <0.001 0.040 (0.006) <0.001
tat and IR under hypoxia.
Figure 1 (See legend on next page.)
Saelen et al. Radiation Oncology 2012, 7:165 Page 4 of 10
http://www.ro-journal.com/content/7/1/165
(See figure on previous page.)
Figure 1 Vorinostat, hypoxia, and ionizing radiation (IR) – in vitro clonogenicity and HIF-1α expression. (A) HCT116, (B) HT29, KM20L2
and SW620 cells were treated with IR under normoxia (IR-NO), IR under hypoxia (IR-HO), vorinostat and IR under normoxia (VOR-IR-NO) or
vorinostat and IR under hypoxia (VOR-IR-HO). Surviving fractions are shown as mean, and bars represent SEM. * Indicates significant difference
between IR-NO and IR-HO. ** Indicates significant difference between VOR-IR-NO and IR-NO. *** Indicates significant difference between VOR-IR-
HO and IR-HO. (C) Western immunoblot analysis of HIF-1α expression in HCT116 cells exposed to normoxia (NO) or hypoxia (HO). Cells were
treated with CoCl2 as a positive control and actin was used as protein loading control.










HO 0.27 ± 1.9 C 0.7
IR-NO 5.47 ± 1.9 C <0.001
IR-HO 2.33 ± 3.0 C 0.09
SW620 Main
experiment
IR-NO 7.83 ± 5.9 C 0.02
IR-HO −1.43 ± 3.6 C 0.4
VOR-IR-HO 6.07 ± 2.5 IR-HO 0.02
TGD2x = tumor growth delay at 2-fold increase of relative tumor volume;
C = control; HO= hypoxia; IR-NO= IR under normoxia; IR-HO= IR under hypoxia;
VOR-IR-HO= vorinostat and IR under hypoxia.
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verified by western immunoblot analysis, showing induc-
tion of HIF-1α after exposure to in vitro hypoxia. In
contrast, IR-HO cells were less sensitive to a radiation
dose of 5 Gy than IR-NO cells (SF were 0.13 ± 0.03 and
0.029 ± 0.004, respectively; p = 0.002). Notably, vorinostat
enhanced the 5-Gy radiation effects of both hypoxic and
normoxic cells (SF for VOR-IR-HO cells was
0.020 ± 0.005; p = 0.003; SF for VOR-IR-NO cells was
0.011 ± 0.004; p = 0.006). The experiments were also per-
formed applying 2-Gy radiation doses, and although the
effects of hypoxia and vorinostat treatment exhibited the
same trends as for the 5-Gy dose, the differences were
not statistically significant (Table 1, Figure 1).
In subsequent experiments, a radiation dose of 5 Gy
was used. Hypoxia alone did not substantially influence
clonogenicity in any of the models. The cytotoxic effect
of vorinostat alone varied among the cell lines (SF 0.66-
0.88), but was not significantly different for VOR-HO
cells compared to VOR-NO cells. Clonogenicity of
IR-HO cells was higher than for the respective IR-NO
counterparts (for HT29, SF 0.51 ± 0.05 versus 0.33 ± 0.02;
p = 0.02; for SW620, SF 0.36 ± 0.10 versus 0.079 ± 0.02;
p = 0.049; for KM20L2, SF 0.20 ± 0.02 versus 0.11 ±
0.002; p = 0.02). Again, in VOR-IR-HO cells compared
to IR-HO cells, vorinostat caused radiosensitization (for
HT29, SF 0.24 ± 0.02 versus 0.51 ± 0.05; p = 0.005; for
SW620, SF 0.052 ± 0.03 versus 0.36 ± 0.10; p = 0.04;
for KM20L2, SF 0.040± 0.006 versus 0.20± 0.02; p =
0.002). Under normoxia (VOR-IR-NO), HT29 and
KM20L2 were radiosensitized by vorinostat, while the ef-
fect was not statistically significant for SW620.
Vorinostat, hypoxia, and IR – in vivo tumor growth
In a pilot experiment, radiation exposure inhibited
growth of normoxic SW620 xenografts but not of hyp-
oxic tumors. 5–6 mice were randomized to each treat-
ment group (control, C; hypoxia, HO: ionizing radiation
under normoxia, IR-NO; ionizing radiation under hyp-
oxia, IR-HO). Experimental treatments were started
17 days after establishment of SW620 xenografts at
tumor volumes of 192.7 ± 112 mm3 (mean ± standard
deviation). Of 23 mice included in the experiment, one
IR-NO animal was excluded from analysis as it was
sacrificed early (day 4) due to anesthesia-related compli-
cations. Untreated xenografts had a T2x of 5.33 ± 2.6 days.The TGD2x of HO tumors was unchanged compared to
C (TGD2x 0.27 ± 1.9 days; p = 0.74). The IR exposure
inhibited growth of normoxic xenografts as IR-NO
tumors were growth inhibited (TGD2x 5.47 ± 1.9 days;
p < 0.001), while the growth rate of IR-HO tumors was
not significantly different from C (TGD2x 2.33 ± 3.0;
p = 0.09) (Table 2, Figure 2).
A subsequent experiment was undertaken to specific-
ally investigate the effects of vorinostat under hypoxia,
involving four treatment groups: C, IR-NO, IR-HO, or
VOR-IR-HO. Experimental treatments were started
13 days after establishment of SW620 xenografts at
tumor volumes of 51.1 ± 35 mm3 (mean± standard devi-
ation). Of 23 mice included in the experiment, four mice
were excluded from analysis as they were sacrificed early
(days 1–2) for the following reasons: anesthesia-related
complications (n= 3; two VOR-IR-HO and one IR-NO)
and failure to thrive (n= 1; VOR-IR-HO), leaving three
animals for analysis in the VOR-IR-HO group. For un-
treated xenografts T2x was 9.60 ± 7.7 days. Similarly to
the pilot findings, radiation exposure inhibited growth
under normoxia but not under hypoxia (for IR-NO
TGD2x was 7.83 ± 5.9 days; p = 0.016 compared to C); for
IR-HO tumors TGD2x was −1.43 ± 3.6; p = 0.40 com-
pared to C)). Importantly, vorinostat enhanced radiosen-
sitivity under hypoxia as growth of the VOR-IR-HO
xenografts was inhibited compared to IR-HO xenografts
(TGD2x was 6.07 ± 2.5 versus −1.43 ± 3.6; p = 0.015).
Time after start of treatment (days)























Time after start of treatment (days)
























Figure 2 Vorinostat, hypoxia, and ionizing radiation (IR) – in vivo tumor growth. (A) Mice bearing SW620 xenografts were treated with
vehicle (control, C), hypoxia (HO), IR under normoxia (IR-NO) and IR under hypoxia (IR-HO). (B) Mice bearing SW620 xenografts were treated with
vehicle (control, C), IR under normoxia (IR-NO), IR under hypoxia (IR-HO), or vorinostat and IR under hypoxia (VOR-IR-HO). Relative tumor volumes
(mean± SEM) presented as function of time after start of treatments.
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To assess the effect of adding vorinostat to
fluoropyrimidine-based CRT, two xenograft models,
SW620 and HCT116, were used. The experimental setup
included seven groups of mice receiving C, VOR, CAP,IR, VOR-IR, CAP-IR, or the full combination of VOR-
CAP-IR. Experimental treatments were initiated 10 days
(SW620) or 14 days (HCT116) after establishment of
xenografts at tumor volumes of 100.8 ± 86 mm3 and
77.0 ± 57 mm3 (mean ± standard deviation), respectively.
Saelen et al. Radiation Oncology 2012, 7:165 Page 7 of 10
http://www.ro-journal.com/content/7/1/165Of 53 mice included in each experiment, five mice were
sacrificed early (days 1–4) because of anesthesia-related
complications (n= 3; SW620) or failure to thrive (n= 2;
HCT116), and were excluded from analysis. Further-
more, due to ulceration of the tumors, three xenografts
did not reach T2x and one vehicle xenograft grew abnor-
mally (HCT116) and were removed from the study
(Table 3, Figure 3).
For untreated xenografts T2x was 4.13 ± 0.9 days for
HCT116 and 4.30 ± 1.3 days for SW620. While IR inhib-
ited growth of HCT116 (TGD2x was 5.68 ± 8.5 days;
p = 0.025 compared to C), growth inhibition of SW620
was not statistically significant (TGD2x was
1.40 ± 2.2 days, p = 0.061 compared to C). Single-agent
therapy with CAP delayed tumor growth compared to C
for HCT116 (TGD2x was 2.68 ± 2.4 days, p = 0.001), but
not for SW620 (TGD2x was 0.14 ± 1.8 days, p = 0.8).
Single-agent therapy with VOR did not alter tumor
growth (for HCT116, TGD2x was 0.24 ± 1.9 days, p = 0.7
compared to C, respectively; for SW620, TGD2x was
0.88 ± 1.9 days, p = 0.2 compared to C. Tumor growth
delay of VOR-IR xenografts was observed for HCT-116
(TGD2x of VOR-IR was 20.06 ± 15.1 days compared to
TGD2x of IR which was 5.68 ± 8.5 days, p = 0.01), while
for SW620 tumor growth was not significantly delayed,
although a similar trend was observed (TGD2x of VOR-
IR was 2.78 ± 2.6 days compared to TGD2x of IR which
was 1.40 ± 2.2 days, p = 0.2). Only minor, non-significant
changes of radiosensitivity was obtained by adding cape-










IR 5.68 ± 8.5 C 0.03
CAP 2.68 ± 2.4 C 0.001
VOR 0.24 ±1.9 C 0.7
CAP-IR 5.46 ± 6.1 IR 0.9
VOR-IR 20.06 ± 15.1 IR 0.01
VOR-CAP-IR 18.99 ± 7.3 CAP-IR <0.001
SW620
IR 1.40 ± 2.2 C 0.06
CAP 0.14 ± 1.8 C 0.8
VOR 0.88 ± 1.9 C 0.2
CAP-IR 2.53 ± 3.1 IR 0.3
VOR-IR 2.8 ± 2.6 IR 0.2
VOR-CAP-IR 5.78 ± 3.9 CAP-IR 0.03
TGD2x = tumor growth delay at 2-fold increase of relative tumor volume;
IR = ionizing radiation;
C = control; CAP = capecitabine; VOR= vorinostat; CAP-IR = capecitabine and IR;
VOR-IR = vorinostat and IR; VOR-CAP-IR = vorinostat, capecitabine and IR.was 5.46 ± 6.1 days compared to TGD2x of IR of
5.68 ± 8.5 days, p = 0.9; for SW620, TGD2x of CAP-IR
was 2.53 ± 3.1 days compared to TGD2x of IR of
1.40 ± 2.2 days, p = 0.2). Notably, vorinostat in combin-
ation with capecitabine improved radiation efficacy in
both models as TGD2x of VOR-CAP-IR xenografts were
significantly increased compared to TGD2x of CAP-IR
xenografts (for HCT116, TGD2x of VOR-CAP-IR was
18.99 ± 7.3 days compared to TGD2x of 5.46 ± 6.1 days
for CAP-IR, p <0.001; for SW620, TGD2x of VOR-CAP-
IR was 5.78 ± 3.9 days compared to TGD2x of
2.53 ± 3.1 days for CAP-IR, p = 0.03).
Discussion
Exposure to hypoxic conditions during radiation made
the cells in our in vitro models more radioresistent, in
line with theories of classical radiobiology stating that
hypoxia increases the resistance of cancer cells to radi-
ation treatment. In vivo, a similar effect of short-term
acute hypoxia was observed, as clamped tumors were
more resistant to treatment with fractionated radiation
than unclamped tumors. Vorinostat enhanced radiosen-
sitivity of cells exposed to hypoxia during radiation in all
colorectal carcinoma cell lines in vitro, almost counter-
balancing hypoxia-induced radioresistance. In line with
these results, vorinostat demonstrated radiosensitizing
effects in xenografts exposed to acute hypoxia, as tumor
volumes of vorinostat-treated mice irradiated under hyp-
oxia were similar to the tumor volumes of mice irra-
diated under normoxia, reversing the radioresistent
hypoxic phenotype.
Response to cancer treatment is strongly influenced
by the tumor microenvironment, and specifically, the
most important determinant of radiotherapy response
is tissue oxygenation. Colorectal tumors are often
large, and analysis of hypoxia biomarkers in patient
samples has revealed that most tumors exhibit a mo-
lecular phenotype consistent with varying hypoxia [11].
Moreover, in a recent report, expression of the
hypoxia-associated protein carbonic anhydrase IX was
negatively associated with CRT response in patients
with rectal cancer [14]. Hence, a likely explanation for
variable CRT response in rectal cancer is variable
tumor oxygenation, and in this perspective, the ability
to overcome hypoxia-related radioresistance would be
an advantageous property of a radiosensitizing drug. In
other tumor forms, a small number of drugs (such as
gemcitabine, irinotecan, and the poly(ADP-ribose)
polymerase-inhibitor velaparib) [15-17] have been eval-
uated in combination with radiotherapy under hypoxic
conditions. Considering the importance of tissue oxy-
genation for radiotherapy efficacy, the scarcity of ex-
perimental data exploring radiosensitizers under
hypoxia in LARC is remarkable. One reason for this
Time after start of treatment (days)
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Figure 3 Vorinostat, capecitabine, and ionizing radiation (IR) – in vivo tumor growth. Mice bearing (A) SW620 and (B) HCT116 xenografts
were treated with vehicle (control, C), vorinostat (VOR), capecitabine (CAP), IR, capecitabine and IR (CAP-IR), vorinostat and IR (VOR-IR), or
vorinostat, capecitabine and IR (VOR-CAP-IR). Relative tumor volumes (mean± SEM) presented as function of time after start of treatments.
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models for mimicking clinical hypoxia when evaluating
radiosensitizing drugs. This challenge was also appar-
ent in our experiments, as the impact of hypoxia on
radioresistance was less pronounced in the pilot than
in the main experiment (Figure 2). This illustrates bio-
logical variation which may be partially explained by
the introduction of a tighter set of hypoxia clamps in
the second experimental series than in the pilot. There
is also some controversy regarding how to conduct
in vivo experiments, particularly when fractionating theradiation. Although the clamping technique has been
shown to be relevant for this purpose [18], it has been
questioned whether this strategy truly reflects radio-
sensitivity under hypoxia [19]. In this context, our ap-
proach of administering vorinostat prior to short-term
hypoxia and irradiation is interesting, as our experi-
ments represent an important attempt to evaluate a
novel radiosensitizer under tumor hypoxia. However,
such experiments should be repeated in larger series
of animals, and with the paucity of data describing the
use of conventional radiosensitizing agents in LARC
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stat in this clinical setting is still elusive.
In LARC, fluoropyrimidine-based neoadjuvant CRT is
the established treatment regimen and any novel radio-
sensitizing agent must be evaluated in this context. In
the present study, in vivo addition of vorinostat to cape-
citabine and fractionated radiation enhanced treatment
efficacy in terms of inhibited tumor growth in two colo-
rectal xenograft models. Vorinostat has recently been
shown to synergize with fluoropyrimidine-based chemo-
therapy in preclinical colorectal carcinoma models
[20,21], but radiosensitizing properties of the combin-
ation has to our knowledge not been evaluated. Applying
radiation in combination with vorinostat or capecitabine
alone, we observed trends towards enhanced radiosensi-
tivity, although the reduction of tumor volume was not
statistically significant. In our previous experiments,
both these drugs were potent radiosensitizers in experi-
mental colorectal carcinoma models [7,22]. The variable
effects on radiosensitivity could be explained by the lim-
ited total treatment doses possible to administer in the
experimental setting, in addition to variation associated
with the biological complexity of animal models. Similar
limitations were also present in the combination group
and in this context, the enhanced radiosensitivity
observed when combining vorinostat and capecitabine is
noteworthy, and adds to the preclinical evidence sup-
porting vorinostat as radiosensitizer in LARC [7,23].
Conclusion
Although preclinical evidence [7,23] and clinical safety
data [8,9] both support the use of vorinostat as radiosen-
sitizer in LARC, more extensive preclinical examination
was necessary prior to recommending vorinostat as an
additional component of CRT in LARC trials. Hence, we
expanded our in vitro and in vivo models by studying
radiosensitizing effects of vorinostat under hypoxic con-
ditions and in combination with capecitabine. Import-
antly, the results from the present study indicate that
vorinostat is a radiosensitizer under hypoxic conditions
and also interacts favorably with capecitabine in experi-
mental models of colorectal carcinoma. Recognizing the
important role of hypoxia in LARC, particularly in large
T4 tumors, as well as the requirement that novel drugs
should be compatible with fluoropyrimidine-based
standard CRT, our results encourage the implementation
of vorinostat in next-generation clinical CRT trials in
LARC.
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